Article
An integrated pathway mutation and clinical model predicts survival in unresectable HCC with hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab.
BMC cancer - 6 Jun 2026
Tang Shuangyan, Cai Hongjie, Wu Zhiqiang, Huang Shuqin, Zhao Lihua, Wu Lijia, Gong Longlong, Guo Wenbo
Abstract excerpt
BACKGROUND: Triple combination therapy consisting of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and tislelizumab has shown encouraging clinical efficacy in patients with advanced hepatocellular carcinoma (HCC). However, robust prognostic models to predict treatment outcomes remain lacking. METHODS: A total of 83 patients with unresectable HCC receiving HAIC combined with lenvatinib and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.